[26] elucidated the connection between RRM2 expression and the immune microenvironment in lung adenocarcinoma (LUAD), suggesting RRM2 as a predictive biomarker for PD‐1/PD‐L1 inhibitors, primarily through the ANXA1/AKT signaling pathway. This evidence concerns the gene RPL17 and lung adenocarcinoma.